Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Complementary and alternative medicines in prostate cancer: from bench to bedside?

Klempner SJ, Bubley G.

Oncologist. 2012;17(6):830-7. doi: 10.1634/theoncologist.2012-0094. Epub 2012 May 22. Review.

2.

Complementary and alternative medicine (CAM) in prostate and bladder cancer.

Philippou Y, Hadjipavlou M, Khan S, Rane A.

BJU Int. 2013 Dec;112(8):1073-9. doi: 10.1111/bju.12062. Review.

3.

The role of PC-SPES, selenium, and vitamin E in prostate cancer.

Das P, Kaplan I.

Oncology (Williston Park). 2002 Mar;16(3):285-91; discussion 291, 295-6, 299-300. Review.

4.

Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.

van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller CJ.

BJU Int. 2016 Apr;117 Suppl 4:17-34. doi: 10.1111/bju.13361. Epub 2016 Feb 22. Review.

5.

Complementary and alternative medicine for advanced prostate cancer.

Rackley JD, Clark PE, Hall MC.

Urol Clin North Am. 2006 May;33(2):237-46, viii. Review.

PMID:
16631462
6.

Complementary and alternative therapies in prostate cancer.

Oh WK, Small EJ.

Semin Oncol. 2002 Dec;29(6):575-84. Review.

PMID:
12516040
7.

Review of vitamin E and selenium in the prevention of prostate cancer: implications of the selenium and vitamin E chemoprevention trial.

Pak RW, Lanteri VJ, Scheuch JR, Sawczuk IS.

Integr Cancer Ther. 2002 Dec;1(4):338-44. Review.

PMID:
14664728
8.

Polyphenols from green tea and pomegranate for prevention of prostate cancer.

Adhami VM, Mukhtar H.

Free Radic Res. 2006 Oct;40(10):1095-104. Review.

PMID:
17015254
9.

Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics.

Boon H, Westlake K, Stewart M, Gray R, Fleshner N, Gavin A, Brown JB, Goel V.

Urology. 2003 Nov;62(5):849-53.

PMID:
14624907
10.

Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study.

Beebe-Dimmer JL, Wood DP Jr, Gruber SB, Douglas JA, Bonner JD, Mohai C, Zuhlke KA, Shepherd C, Cooney KA.

Urology. 2004 Feb;63(2):282-7.

PMID:
14972472
11.

[Use of antioxidant and other complementary medicine by patients treated by antitumor chemotherapy: a prospective study].

Thomas-Schoemann A, Alexandre J, Mongaret C, Azibi S, Dauphin A, Goldwasser F, Lemare F.

Bull Cancer. 2011 Jun;98(6):645-53. doi: 10.1684/bdc.2011.1375. French.

12.

Cancer chemoprevention by pomegranate: laboratory and clinical evidence.

Adhami VM, Khan N, Mukhtar H.

Nutr Cancer. 2009;61(6):811-5. doi: 10.1080/01635580903285064. Review.

13.

Role of vitamins, minerals and supplements in the prevention and management of prostate cancer.

Santillo VM, Lowe FC.

Int Braz J Urol. 2006 Jan-Feb;32(1):3-14. Review.

14.

Can we prevent prostate cancer?

Chong P, Rashid P.

Aust Fam Physician. 2005 Apr;34(4):265-7. Review.

PMID:
15861749
15.

Complementary and alternative medicine in prostate cancer.

Jacobson JS, Chetty AP.

Curr Oncol Rep. 2001 Sep;3(5):448-52. Review.

PMID:
11489247
16.

Critical review of complementary therapies for prostate cancer.

Wilkinson S, Chodak GW.

J Clin Oncol. 2003 Jun 1;21(11):2199-210. Review.

PMID:
12775747
17.

Ellagic acid, pomegranate and prostate cancer -- a mini review.

Bell C, Hawthorne S.

J Pharm Pharmacol. 2008 Feb;60(2):139-44. doi: 10.1211/jpp.60.2.0001. Review.

PMID:
18237460
18.

Complementary and alternative medicine use in radiotherapy: what are patients using?

Gillett J, Ientile C, Hiscock J, Plank A, Martin JM.

J Altern Complement Med. 2012 Nov;18(11):1014-20. doi: 10.1089/acm.2011.0334. Epub 2012 Aug 20.

PMID:
22906192
19.

A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach.

Choan E, Segal R, Jonker D, Malone S, Reaume N, Eapen L, Gallant V.

Urol Oncol. 2005 Mar-Apr;23(2):108-13.

PMID:
15869995
20.

Complementary and alternative medicine use by patients enrolled onto phase I clinical trials.

Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA.

J Clin Oncol. 2004 Dec 1;22(23):4810-5. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248.

PMID:
15570083

Supplemental Content

Support Center